Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 14, 2024
- Oral Fadraciclib Phase 2 Proof of Concept Study Enrolling Well -
- 065-101 PoC Interim Data Anticipated in the Fourth Quarter of 2024 -
- Management to Host Conference Call at 4:30 pm EDT Today -
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (7/18/2025, 8:00:01 PM)
After market: 5.12 -0.37 (-6.78%)5.4923
+0.18 (+3.43%)
13.07
+4.84 (+58.81%)
Find more stocks in the Stock Screener
